Medpin, or medicine for people in need, began in 1999 as a project of the Public Health Institute. During its eight-year tenure, Medpin worked with a broad group of California clinics, pharmacy schools, and health care foundations to get people appropriat

Good news for American Indians yesterday, as the U.S. Senate passed the Indian Health Care Improvement Act by an 83-10 margin.  A similar version must still get through two House committees before it makes it to the floor. The act, S. 1200, would distribu

The devil, they say, is in the details.  So we were interested to see the tripartite approach the University of New Mexico recently took when it came to weaning itself off industry grub (Go Lobos!) The University of New Mexico Health Sciences Center recen

The Senate Special Committee on Aging holds a hearing today on marketing by medical device companies. The hearing concerns the business practices of five companies involved in a $311 million settlement with the U.S. government last year over kickback all

On Monday, The Boston Globe ran this editorial, "A line between docs and drugs," as the third part of a series called Priced out of Care.  The editorial, which features the work of the Prescription Project with local academic medical centers to build conf

On February 14, we reported that the Federal Trade Commission is suing Cephalon (NasdaqGS:CEPH) for paying off four generic drug companies not to bring a generic version of its sleepiness drug, Provigil to market. Several of our coalition members have be

Photo: CSEA President Danny Donohue joins childcare providers from CCPT-NY/CSEA and organizers in celebration of an overwhelming election victory. PAL extends an enthusiastic congratulations to the Civil Service Employees Association (CSEA), a member of

The Boston Globe today ran "A line between docs and drugs," an editorial that featured our colleagues at the Prescription Project. The editorial lauded academic medical centers that are implementing policies restricting the "freebies" and other marketing

On Friday, we posted a press release from Breast Cancer Action (Breast Cancer Action: Patients Lose, Genentech Wins with FDA’s Avastin Ruling) criticizing the FDA's approval of Genentech's [NYSE:DNA] Avastin for treatment of metastatic breast cancer. We